Sarcoma  >>  Erivedge (vismodegib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Erivedge (vismodegib) / Roche
NCT00980343: GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

Completed
2
44
US
vismodegib, Erivedge, GDC-0449, Hedgehog antagonist GDC-0449, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study
National Cancer Institute (NCI)
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
05/12
06/12
2010-019817-20: A phase II study of GDC-0449 in patients with advanced chondrosarcomas.

Ongoing
2
41
Europe
GDC-0449, 27887,
Institut Bergonié
Adult patients with unresectable locally advanced or metastatic chondrosarcomas.
 
 
NCT01267955: Vismodegib in Treating Patients With Advanced Chondrosarcomas

Active, not recruiting
2
45
Europe
Laboratory Biomarker Analysis, Pharmacogenomic Study, PHARMACOGENOMIC, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449
National Cancer Institute (NCI)
Clear Cell Chondrosarcoma, Dedifferentiated Chondrosarcoma, Locally Advanced Chondrosarcoma, Mesenchymal Chondrosarcoma, Metastatic Chondrosarcoma, Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
06/18
07/24

Download Options